Novartis has agreed to acquire Myricx Bio for $1.1 billion upfront, plus up to $400 million in milestone payments, to gain access to the company’s novel N-myristoyltransferase inhibitor payload platform and two lead antibody-drug conjugate programs. The deal, announced this week, reinforces the continued industry demand for innovative antibody technologies capable of addressing limitations of existing cancer therapies.
The transaction is the latest in a series of multibillion-dollar antibody therapeutics deals, including Jazz Pharmaceuticals’ collaboration with AbCellera, Gilead Sciences’ acquisition of Tubulis, and multiple other ADC licensing agreements. These investments highlight the strategic importance of differentiated antibody platforms in the pharmaceutical landscape.
VERAXA Biotech (NASDAQ: VRXA) operates in one of biotechnology’s most active partnering environments, with pharmaceutical companies committing billions to differentiated antibody therapeutics. The company is advancing proprietary antibody therapeutics spanning both ADCs and T-cell engagers through its patented BiTAC platform, positioning it within two therapeutic categories that continue to attract significant pharmaceutical investment, strategic collaborations, and acquisition activity.
The Novartis-Myricx deal is a clear signal that the industry is willing to pay top dollar for next-generation ADC technologies. Myricx Bio’s NMTi payload platform offers a novel mechanism of action that could overcome limitations of conventional ADCs, such as drug resistance and off-target toxicity. For VERAXA, this validates the potential of its own ADC programs and the broader BiTAC platform, which is designed to enhance the efficacy and safety of bispecific antibodies.
VERAXA’s BiTAC platform is a registered trademark of VERAXA Biotech GmbH, and the company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research. The company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond, guided by rigorous quality-by-design principles.
For investors, the Novartis acquisition underscores the value that large pharma places on innovative antibody platforms. As more multibillion-dollar deals occur, companies like VERAXA that have proprietary technology in ADCs and T-cell engagers may become attractive targets for collaboration or acquisition. The deal also highlights the growing trend of pharmaceutical companies seeking to bolster their oncology pipelines with novel mechanisms of action.
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. The press release also notes that certain statements are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties that may cause actual results to differ materially.
